Pretreatment with IFN-α increases resistance to imatinib mesylate in patients with chronic myelocytic leukemia

Acta Pharmacol Sin. 2012 Jul;33(7):979-80. doi: 10.1038/aps.2012.43. Epub 2012 Jun 11.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Drug Resistance, Neoplasm / drug effects*
  • Humans
  • Imatinib Mesylate
  • Immunologic Factors / pharmacology*
  • Immunologic Factors / therapeutic use
  • Interferon-alpha / pharmacology*
  • Interferon-alpha / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Piperazines / pharmacology*
  • Piperazines / therapeutic use
  • Point Mutation / drug effects
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrimidines / pharmacology*
  • Pyrimidines / therapeutic use
  • Retrospective Studies

Substances

  • Antineoplastic Agents
  • Benzamides
  • Immunologic Factors
  • Interferon-alpha
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate